ClinicalTrials.gg
CompletedNCT02307461Updated Mar 17, 2021

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

A Phase 1 interventional study of IPI-145 (duvelisib) and IPI-145 in Healthy, sponsored by SecuraBio. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-17.

Sponsored by SecuraBio · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

To Evaluate the Bioequivalence of the two formulations of IPI-145 and the Effect of Food on the Pharmacokinetics of IPI-145

Read the detailed description

This Phase 1, randomized, open-label study of IPI-145 will be conducted in 2 parts.

Part 1 will be conducted in 2 cohorts. Cohort 1 will consist of 32 healthy subjects, and Cohort 2 will consist of 52 healthy subjects. Subjects in each cohort will receive 2 doses of IPI under fasted conditions in a 2-period, 2-sequence crossover design. Dosing in Period 1 and Period 2 will be separated by at least 7 days.

Part 2 is a 2-period, 2-sequence crossover design to assess the effect of a high-fat meal on the PK of the IPI-145 in 20 subjects. Subjects will receive single oral doses under fed (high-fat meal) and fasted conditions, separated by at least 7 days.

02

Conditions studied

  • Healthy

Keywords

  • Phase 1
  • Bioequivalence
  • Pharmacokinetics
  • Food
  • Healthy Adult
03

In context

Lead sponsor

SecuraBio is the lead sponsor of 25 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women of non-child bearing potential between 18-50 years of age
  • (BMI): 18.0 - 32.0 kg/m2.
  • Healthy subjects: in good health, determined by no findings from clinical evaluations
  • Provided written prior to any study specific procedures

Exclusion criteria

Exclusion Criteria:

  • Women of
  • Healthy subjects: positive screening test for surface antigen, antibody, or -1/HIV-2 antibodies
  • at screening showing ≥ 450 msec
  • Evidence of medical conditions
  • History of gastrointestinal disease or surgery that may affect drug absorption
  • Positive T-Spot (tuberculosis)TB test at screening
  • Any active infection at the time of screening or admission
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Part 1 Cohort 1

    IPI-145 test formulation (capsule) high single dose and IPI-145 reference formulation (capsule) high single dose

    Drug: IPI-145 (duvelisib)

  • Experimental
    Part 1 Cohort 2

    IPI-145 test formulation (capsule) low single dose and IPI-145 reference formulation (capsule) low single dose

    Drug: IPI-145

  • Experimental
    Part 2 Cohort 3

    IPI-145 test formulation (capsule) high single dose administered under fasted and fed conditions

    Drug: IPI-145

Interventions

  • High single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) high single oral dose

  • Low single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) low single oral dose

  • High single oral dose IPI-145 test formulation (capsule) with a high-fat meal and without food

06

What researchers measure

Primary outcomes

  1. Assessment of bioequivalence of the IPI-145 test and reference formulations

    Time frame: 24 Hours

  2. Pharmacokinetic Parameter (AUClast ) of IPI-145

    Time frame: Over 24 hours

  3. Pharmacokinetic Parameter (AUCinf ) of IPI-145

    Time frame: Over 24 hours

  4. Pharmacokinetic Parameter (Cmax) of IPI-145

    Time frame: Over 24 hours

Secondary outcomes

  1. Incidence of adverse events following administration of IPI-145

    Time frame: 7 weeks

07

Study locations

1 site
  • Lenexa, Kansas 66219, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2014
First posted
Dec 4, 2014
Start
Nov 2014
Primary completionActual
Aug 2015
CompletionActual
Sep 2015
Last update
Mar 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02307461
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
Dec 4, 2014
Start date
Nov 2014
Primary completion
Aug 2015
Completion
Sep 2015
Last update
Mar 17, 2021

Study contacts

Hagop Youssoufian, MD
study chair · Verastem, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion